L01XX77 • adagrasib • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Adagrasib is a medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. It is a specific inhibitor of the KRAS G12C mutation, which plays a key role in cancer cell growth and survival.
The medication is taken orally, usually once or twice daily, as directed by a doctor. Adagrasib has shown efficacy in reducing tumor size and slowing disease progression in patients with this specific mutation.
Common side effects include nausea, diarrhea, fatigue, and elevated levels of certain liver enzymes. In rare cases, it may cause severe liver toxicity or other serious adverse reactions.
Patients taking adagrasib should be regularly monitored for liver function and report any side effects or unusual symptoms to their doctor.
Substance: adagrasib
Date of last drug list: 01-04-2026
Commercial code: W71715001
Concentration: 200mg
Pharmaceutical form: film-coated tablets
Quantity: 180
Product type: generic
Price: 59750.56 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: SWORDS LABORATORIES UNLIMITED COMPANY T/A - IRLANDA
Holder: C.N. UNIFARM S.A. - ROMANIA
Number: 1174/2026/01
Shelf life: 2 years